Sciclone Pharmaceuticals, Inc. (SCLN) Misses Q3 EPS by 1c; Lowers FY12 Outlook
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Join SI Premium – FREE
Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q3 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $40.7 million versus the consensus estimate of $44.8 million.
Sciclone Pharmaceuticals, Inc. sees FY2012 EPS of $0.62-0.68, versus prior guidance of $0.72-0.78 and the consensus of $0.75. Sciclone Pharmaceuticals, Inc. sees FY2012 revenue of $152-157 million, versus prior guidance of $165-170 million and the consensus of $171.68 million.
For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.
Sciclone Pharmaceuticals, Inc. sees FY2012 EPS of $0.62-0.68, versus prior guidance of $0.72-0.78 and the consensus of $0.75. Sciclone Pharmaceuticals, Inc. sees FY2012 revenue of $152-157 million, versus prior guidance of $165-170 million and the consensus of $171.68 million.
For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Diana Shipping drops bid for Genco after price demands spike to $36.91
- SanDisk upgraded at JPMorgan after investor day; shares climb
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
